Pfizer bags EU approval for breast cancer drug Ibrance

European regulators have cleared use of Pfizer's Ibrance to treat women with locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor recep…
Read the full story: PharmaTimes: News RSS